Table 2 Factors affecting the progression-free survival and overall survival in patients after anti-PD-1 therapy based on multivariate analysis.

From: Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer

Variable

Category

Multivariate survival analysis Progression-free survival

Multivariate survival analysis Overall survival

AHR

95% CI

P

AHR

95% CI

P

Age (years)

≥65 vs. <65

1.273

0.709–2.284

0.419

1.147

0.629–2.092

0.655

Sex

Women vs. Men

0.812

0.428–1.540

0.523

1.127

0.569–2.233

0.732

EGFR status

Mutant vs. wild-type

2.158

0.954–4.882

0.065

2.563

1.083–6.063

0.032

PD-L1

 ≥ 1% vs. <1%

0.878

0.505–1.528

0.646

0.689

0.375–1.264

0.228

NMR

 ≥ 5.75% vs. <5.75

0.198

0.095–0.413

0.0001

0.369

0.190–0.719

0.003

  1. Abbreviations: EGFR, epidermal growth factor receptor; NMR, NK cells to Lox-1+PMN-MDSC ratio; AHR, adjusted hazard ratio; CI, confidence interval.
Back to article page